Peptide Asparaginyl Ligases

·  More than 10 years of Research and Development on peptide asparaginyl ligases (PALs) by Singzyme Founders and collaborators at N.T.U (Singapore) have cumulated in a wealth of expertise and proprietary knowledge on this class of enzymes. 

·  Singzyme secured a set of exclusive, worldwide licenses from patents filed by Singzyme founders and collaborators (Table 1) to exploit PALs for fast and precision bioconjugation. 

·  Singzyme’s reliable and versatile bioconjugation technology opens new frontiers for developing next generation bioconjugates such as antibody-drug conjugates (ADCs) and radionuclide drug conjugates (RDCs) for cancer imaging and therapy. 

2024

·  ICMI group (Brussels) led by Nick de Voogdt and N.T.U Julien Lescar report the patent application of nanobody bioconjugation for cancer imaging and therapy (SG Patent Application No. 10202300550Y, “Asparaginyl Peptide Ligase-Mediated Radiolabelling Of Nanobodies”, filed 01 March 2024). 

2023 

·  N.T.U. groups led by Chuan Fa Liu, Julien Lescar and James P. Tam demonstrate that a cascade enzymatic reaction using the glutaminyl cyclase dramatically improves the yield of the bioconjugation reaction (Xia Y., et al., 2023. JACS; PCT No. WO2023191726A1).

·  Singzyme obtains exclusive worldwide license for glutaminyl cyclase for applications in all fields on 1stOct.

2022 

·  Lonza and Singzyme Announce Collaboration Agreement 

(https://www.lonza.com/media-advisories/lonza-singzyme-announce-collaboration-accelerate-development-bioconjugates) on 31st Oct.

·  Singzyme obtains exclusive worldwide license for Quicklase for field of use in therapeutic, diagnostic, or theranostic agents (including antibody-small molecule conjugates) on 28th Oct.

·  Patent on Butelase-1 granted in China (CN106459160B).

2021 

·  Singzyme is incorporated in Singapore on 22nd April.

·  Singzyme obtains exclusive worldwide licenses for VyPAL2 and Butelase-1 for applications in all fields on 10th Sept.

2020

·  Patents on Butelase-1 granted in Europe (EP3134427B1); Japan (JP6708556B2); US (US10590407B2; US11124788B2).

2019   

·  Discovery of VyPAL2 by N.T.U. groups of James P. Tam, Julien Lescar and Chuan Fa Liu (Hemu X., et al. PNAS. 2019. doi: 10.1073/pnas.1818568116; PCT No. WO 2020226572 A1)

2017 

·  N.T.U. groups led by Julien Lescar and Bin Wu engineered Quicklase, the first hyperactive recombinant PAL (Yang R., et al 2017. JACS. doi: 10.1021/jacs.6b12637; Patents granted in US (11795488B2) and China (CN109790205B).

2014 

·  First peptide asparaginyl ligase, Butelase-1, responsible for peptide cyclization is discovered in a plant in Singapore by N.T.U. group of James P. Tam (Nguyen G.K., et al., 2014. doi: 10.1038/nchembio.1586